Products
Lenzilumab Biosimilar Monoclonal Antibody (GM-CSF) for Research
Pre-Made Lenzilumab biosimilar, Whole mAb, Anti-CSF2 Antibody: Anti-CSF/GMCSF therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Lenzilumab (INN; development code KB003)[1] is a humanized monoclonal antibody (class IgG1 kappa)[2] that targets colony stimulating factor 2 (CSF2)/granulocyte-macrophage colony stimulating factor (GM-CSF).
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-303-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Lenzilumab biosimilar, Whole mAb, Anti-CSF2 Antibody: Anti-CSF/GMCSF therapeutic antibody |
| INN Name | Lenzilumab |
| Target | CSF2 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Preregistration |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2014 |
| Year Recommended | 2015 |
| Companies | Humanigen;KaloBios Pharmaceuticals |
| Conditions Approved | na |
| Conditions Active | COVID-19;Cytokine release syndrome;B-cell lymphoma;Drug hypersensitivity;Precursor cell lymphoblastic leukaemia-lymphoma;Graft-versus-host disease |
| Conditions Discontinued | Asthma;Rheumatoid arthritis;Chronic myelomonocytic leukaemia;Solid tumours |
| Development Tech | Humaneering Technology |
About target - CSF2
1. Protein Granulocyte-macrophage colony-stimulating factor
2. Gene CSF2
3. Organism Homo sapiens (Human)
Function
Cytokine that stimulates the growth and differentiation of hematopoietic precursor cells from various lineages, including granulocytes, macrophages, eosinophils and erythrocytes.
